Anavex Life Sciences (NASDAQ:AVXL) Earns Buy Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Anavex Life Sciences (NASDAQ:AVXL - Free Report) in a report released on Tuesday,Benzinga reports. HC Wainwright currently has a $42.00 price target on the biotechnology company's stock. HC Wainwright also issued estimates for Anavex Life Sciences' Q2 2025 earnings at ($0.16) EPS, Q3 2025 earnings at ($0.18) EPS, Q4 2025 earnings at ($0.20) EPS, FY2025 earnings at ($0.69) EPS, Q1 2026 earnings at ($0.18) EPS, Q2 2026 earnings at ($0.17) EPS, Q3 2026 earnings at ($0.16) EPS, Q4 2026 earnings at ($0.15) EPS and FY2026 earnings at ($0.66) EPS.

Separately, D. Boral Capital reiterated a "buy" rating and issued a $46.00 price objective on shares of Anavex Life Sciences in a research report on Wednesday, February 12th.

Anavex Life Sciences Trading Down 3.8 %

AVXL stock traded down $0.33 during mid-day trading on Tuesday, hitting $8.35. 1,126,061 shares of the company were exchanged, compared to its average volume of 957,895. The company has a market capitalization of $710.25 million, a PE ratio of -15.18 and a beta of 0.69. Anavex Life Sciences has a twelve month low of $3.25 and a twelve month high of $14.44. The firm has a fifty day simple moving average of $9.97 and a 200 day simple moving average of $7.78.

Anavex Life Sciences (NASDAQ:AVXL - Get Free Report) last posted its quarterly earnings results on Wednesday, February 12th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.17) by $0.03. As a group, sell-side analysts anticipate that Anavex Life Sciences will post -0.69 earnings per share for the current year.

Institutional Trading of Anavex Life Sciences

Several hedge funds have recently bought and sold shares of the company. Vermillion Wealth Management Inc. bought a new stake in shares of Anavex Life Sciences during the 4th quarter worth about $34,000. Tower Research Capital LLC TRC raised its position in shares of Anavex Life Sciences by 102.0% during the 4th quarter. Tower Research Capital LLC TRC now owns 3,383 shares of the biotechnology company's stock worth $36,000 after buying an additional 1,708 shares in the last quarter. Orion Capital Management LLC grew its stake in shares of Anavex Life Sciences by 666.7% in the 3rd quarter. Orion Capital Management LLC now owns 11,500 shares of the biotechnology company's stock worth $65,000 after purchasing an additional 10,000 shares during the last quarter. PVG Asset Management Corp acquired a new position in shares of Anavex Life Sciences in the 3rd quarter worth approximately $74,000. Finally, Atria Investments Inc acquired a new position in shares of Anavex Life Sciences in the 3rd quarter worth approximately $76,000. 31.55% of the stock is currently owned by institutional investors.

About Anavex Life Sciences

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.